Voluntary announcement abstracts of six studies published at 2026 ESMO
Filed with HKEX · Stock code 9887 · · 5 pages · English
Summary by 6ix AI
Notably, three studies have been selected for Proffered Paper presentations, including one as a Late-Breaking Abstract. The announcement aims to inform shareholders and potential investors about the latest developments in the company's research and clinical trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Nanjing Leads Biolabs Co., Ltd. on 6ix
Earlier from Nanjing Leads Biolabs
- Voluntary announcement first patient enrolled in phase ib/II clinical trial of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) in combination therapy for metastatic colorectal cancer
- Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Fast Track Designation by the U.S. FDA for first-line treatment of advanced biliary tract cancer
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
- Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Orphan Drug Designation in Japan
Later from Nanjing Leads Biolabs
All Nanjing Leads Biolabs news releasesFollow Nanjing Leads Biolabs into a list and get an email when it puts out news.
Follow Nanjing Leads Biolabs